BioMarin/$BMRN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioMarin
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
- Ticker
- $BMRN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,221
- Headquarters
- San Rafael, United States
- Website
- www.biomarin.com
BioMarin Metrics
BasicAdvanced
$11B
154.39
$0.38
0.23
-
Price and volume
Market cap
$11B
Beta
0.23
52-week high
$70.98
52-week low
$49.26
Average daily volume
2.3M
Financial strength
Current ratio
2.387
Quick ratio
1.163
Long term debt to equity
0.558
Total debt to equity
0.665
Interest coverage (TTM)
5.98%
Profitability
EBITDA (TTM)
645.319
Gross margin (TTM)
50.97%
Net profit margin (TTM)
2.14%
Operating margin (TTM)
14.67%
Effective tax rate (TTM)
51.06%
Revenue per employee (TTM)
$1,060,000
Management effectiveness
Return on assets (TTM)
3.26%
Return on equity (TTM)
1.18%
Valuation
Price to earnings (TTM)
154.387
Price to revenue (TTM)
3.307
Price to book
1.79
Price to tangible book (TTM)
14.4
Price to free cash flow (TTM)
15.538
Free cash flow yield (TTM)
6.44%
Free cash flow per share (TTM)
3.766
Growth
Revenue change (TTM)
11.20%
Earnings per share change (TTM)
-88.85%
3-year revenue growth (CAGR)
15.09%
10-year revenue growth (CAGR)
13.34%
3-year earnings per share growth (CAGR)
-10.29%
10-year earnings per share growth (CAGR)
-19.33%
What the Analysts think about BioMarin
Analyst ratings (Buy, Hold, Sell) for BioMarin stock.
Analyst projections of the future price of BioMarin stock.
Bulls say / Bears say
BioMarin raised its 2026 revenue and adjusted EPS forecasts, citing strong first-half results and demand; it now expects VOXZOGO revenue of $1.0–$1.05 billion. This points to continuing growth in its established franchise. (BioMarin)
The Amicus acquisition adds GALAFOLD and POMBILITI + OPFOLDA to BioMarin’s portfolio, helping metabolic-condition revenue rise 25% in the second quarter. BioMarin also expects substantial cost savings as it integrates the products. (BioMarin)
VOXZOGO met its Phase 3 primary endpoint in hypochondroplasia and improved several growth measures, including standing height and arm span. Approval could open a new indication, with a potential launch in 2027. (BioMarin)
VOXZOGO faces a newer rival that is given weekly rather than daily, which could make it harder to retain patients and defend sales. The changing competitive landscape has also contributed to BioMarin narrowing some VOXZOGO development plans. (Fierce Pharma)
Despite 20% second-quarter revenue growth, GAAP net income fell to $45 million from $241 million and adjusted income also declined. BioMarin attributed the pressure in part to Amicus integration costs and higher interest expense on acquisition financing. (BioMarin)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
BioMarin Financial Performance
Revenues and expenses
BioMarin Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioMarin News
AllArticlesVideos
Funds containing BioMarin
AllUSDEURGBP
Fund name | Fund size | $BMRN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.72% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.71% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.32% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.32% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.